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Abstract
Cytokines play an important role in ischemic injury and repair. However, little is known about their prognostic value in
cardiovascular disease. The aim of this study was to investigate the prognostic importance of chemokines CCL3/MIP-1a,
CCL5/RANTES and CCL18/PARC for the risk of future cardiovascular events in patients with acute coronary syndromes (ACS).
Baseline levels of CCL3/MIP-1a, CCL5/RANTES and CCL18/PARC were determined in ACS patients from the Bad Nauheim
ACS II registry (n=609). During the following 200 days, patients were monitored for the occurrence of fatal and non-fatal
cardiovascular events. Patients with CCL3/MIP1a, CCL5/RANTES and CCL18/PARC concentrations in the highest tertile were
associated with an increased risk of a fatal event during follow-up (HR: 2.19, 95%CI: 1.04–4.61 for CCL3/MIP1a, HR: 3.45,
95%CI: 1.54–7.72 for CCL5/RANTES and HR: 3.14, 95%CI: 1.33–7.46 for CCL18/PARC). This risk was highest for patients with
all three biomarkers concentrations in the upper tertile (HR: 2.52, 95%CI: 1.11–5.65). Together with known risk predictors of
cardiovascular events, CCL3/MIP-1a, CCL5/RANTES and CCL18/PARC combined improved the c-statistics from 0.74 to 0.81
(p=0.007). In conclusion, CCL3/MIP-1a, CCL5/RANTES and CCL18/PARC are independently associated with the risk of short-
term mortality in ACS patients. Combining all three biomarkers further increased their prognostic value.
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Introduction
Cardiovascular diseases continue to be a major cause of
morbidity and mortality in Western societies [1]. Clinically evident
cardiovascular disease is generally attributable to atherothrombo-
sis and often manifests itself by acute coronary syndromes, such as
unstable angina pectoris (UAP) and acute myocardial infarction
(AMI). ACS patients have a considerably increased risk of
secondary cardiovascular events during follow-up, including
recurrent ischemia, myocardial (re)infarction, stroke, embolization
and (re)stenosis-related stable angina pectoris. For adequate
treatment and patient monitoring it is pivotal to distinguish
between individuals with a low and a high risk of secondary events.
This risk stratification has long relied on demographic and other
classic patient factors [2,3], but is now increasingly supported by
several biomarkers, such as troponin T (TnT) and C-reactive
protein (CRP) [4,5]. Still, the markers performance of predicting
future risk at the level of the patient is only moderate and warrants
further investigation into new prognostic biomarkers.
Chemokines, a class of chemotactic cytokines, come into play in
response to acute cardiovascular events, coordinating inflamma-
tion, necrosis, neovascularisation and leukocyte recruitment
[6,7,8]. Amongst other processes, leukocyte recruitment and
infiltration are vital at all stages of atherosclerosis [9]. It has been
shown that several chemokines, including CCL3/MIP1a, CCL5/
RANTES, and CCL18/PARC, are expressed in atherosclerotic
lesions [10,11,12,13]. CCL5/RANTES is produced by various
leukocyte subsets in response to inflammatory stimuli, such as
monocytes, macrophages and T cells, but also smooth muscle cells
[9,14]. CCL3/MIP1a and CCL5/RANTES are released by
activated platelets and are implied to contribute to attraction of
leukocytes in atherothrombosis [7,15]. Indeed genetic deletion of
CCR5, an important receptor for CCL3/MIP1a and CCL5/
RANTES, protected atherosclerotic prone mice from atheroscle-
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[16,17]. Inflammatory stimuli were recently shown to induce
CCL3/MIP1a-mediated neutrophil migration towards sites of
inflammation. In turn, circulating neutrophil numbers have been
reported to be a prognostic factor for future cardiovascular events
[18,19]. CCL18/PARC has specific chemotactic activity on T
cells and this chemokine can activate fibroblasts, thereby directly
contributing to lung fibrosis and possibly myocardial fibrosis upon
ischemia [20]. Furthermore, various chemokines have been
suggested to play a direct role in post-ischemic injury repair after
AMI, not only directly - by mediating the recruitment of
neutrophils, mast cells and stem cells to the lesion - but also
indirectly - by modulating necrosis and angiogenesis
[21,22,23,24,25,26,27].
In only few (genetic) epidemiological studies chemokine
concentrations have been studied in association with ACS
[28,29,30,31,32]. The most elaborately studied chemokines in
atherosclerosis, CCL2/MCP-1 and CCL5/RANTES, have been
implied to reflect the burden of atherosclerotic lesions in
cardiovascular disease patients [30,32]. Different genetic poly-
morphisms for CCL5/RANTES were identified as either harmful
or protective for the development of cardiovascular disease
[31,33,34,35]. Recently, we reported elevated serum levels of
CCL5/RANTES and CCL18/PARC in a small patient cohort
consisting of subjects with unstable angina pectoris and both
chemokines were identified as markers of refractory UAP [32]. In
a similar patient population we showed that CCL3/MIP-1a levels
were highly elevated in patients with AMI and with UAP. In
addition, we observed that CCL3/MIP-1a was a prognostic factor
of future cardiovascular events [36].
In an effort to study the potential of chemokine markers for risk
stratification in ACS, we examined the prognostic value of baseline
levels of CCL3/MIP-1a, CCL5/RANTES and CCL18/PARC in
a prospective cohort of 762 ACS patients. The occurrence of both
fatal and non-fatal cardiovascular events was assessed after a
follow-up period of 200 days. We hypothesized that high blood
concentrations of these biomarkers are associated with an
increased risk of adverse cardiovascular outcomes.
Methods
Ethics Statement
This study complies with the guidelines in the Declaration of
Helsinki. Ethics approval was granted by the regional ethics
committee. All participants gave full informed written consent,
which included consent for biomarker analysis prior to inclusion
into the study.
Study Population
Between April 2005 and November 2006, all consecutive
patients admitted to the Kerckhoff Heart Centre in Bad Nauheim
(Germany) were recruited for the Bad Nauheim ACS II registry.
Patients, on suspicion of acute coronary syndromes (ACS) with
chest pain complaints within the last 48 hours and referred for
early coronary angiography or primary percutaneous intervention
(PCI), were eligible for inclusion (n=762). Admission took place
either directly through the emergency medical system or through
transferral from community hospitals. Patients with multi-vessel
disease and cardiogenic shock were excluded from inclusion. A
diagnosis of UAP, non-ST elevation myocardial infarction
(NSTEMI) or STEMI was made by the treating physician based
on the electrocardiogram (ECG) in combination with serial TnT
measurement as defined by the European Society of Cardiology/
American College of Cardiology guidelines from the year 2000
[37]. Blood was drawn upon admission, prior to angiography and
revascularization procedures. Pre-treatment with clopidogrel or a
GP IIb/IIIa inhibitor was left to the discretion of the treating
physician. Each patient provided information concerning medical
history and medication regime. Baseline ECG characteristics were
recorded, the presence or absence of several cardiovascular risk
factors was assessed and all patients were subjected to a physical
examination. In addition, time from the onset of symptoms until
the time of first blood withdrawal was ascertained.
All patients were monitored for 200 days. Follow-up end points
were a new ACS (e.g. cardiac ischemia and AMI) and coronary
revascularisation (PCI and CABG), which were combined as non-
fatal events. The fatal events comprised all cases of all-cause
mortality. Patients were considered to be at risk for a fatal or non-
fatal event from the date of entry into the study until the date at
which the event occurred. Otherwise, follow-up ended at the date
of withdrawal from the study or at 200 days after entry.
Biochemical Analyses
Baseline blood specimens were centrifuged within one hour
after collection and the serum was snap frozen and stored at
270uC until further analyses. Samples were available for 706
(93%) patients.
Baseline serum levels of CCL3/MIP-1a, CCL5/RANTES and
CCL18/PARC were determined by commercially available
ELISA kits according to the manufacturers’ protocol. ELISA kits
were obtained from Invitrogen (Breda, the Netherlands; human
RANTES/CCL5 ELISA kit, #4.7% intra-assay variation) and
R&D systems (Abingdon, United Kingdom; Human CCL3/MIP-
1 alpha Quantikine ELISA Kit, #8.9% intra-assay variation and
Human CCL18/PARC DuoSet). Cardiac TnT was measured by
electrochemiluminescence immunoassay (third generation for
TnT, ,10%CV, Elecsys, Roche Diagnostics, Mannheim, Ger-
many). NT-proBNP was assessed by electrochemiluminescence
immunoassay (Elecsys proBNP (#2.7% intra-assay variation)
Roche Diagnostics). hsCRP was measured using a near-infrared
particle immunoassay rate method (,5% intra-assay variation)
with the use of the Beckman LX-20pro (Beckman Coulter, Inc).
Creatine Kinase isoenzyme MB was determined by an in vitro
immuno-inhibition assay (,10% intra-assay variation) on a
Figure 1. Kaplan-Meier curves for the occurrence of fatal and
non-fatal events in patients with acute coronary syndromes of
the Bad-Nauheim ACS II registry. P,0.001 for the comparison of
both event functions by the log-rank test.
doi:10.1371/journal.pone.0045804.g001
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Diagnostics).
Statistical Analysis
Data analysis was based on 609 subjects with complete
information available on biomarker concentrations and other
baseline patient characteristics. Patients with and without a
cardiovascular event during follow-up were compared for
differences in baseline characteristics. Regarding nominal vari-
ables, we used the x
2 test for comparisons of proportions. For
continuous variables with a normal distribution we applied the
Student’s t-test for independent samples or analysis of variance
(ANOVA). For continuous variables that were not normally
distributed, we used nonparametric Kruskal-Wallis test.
Associations between chemokine levels and the risk of future
cardiovascular events, hazard ratios (HR) and 95% confidence
intervals (CI) were estimated using Cox proportional hazards
models. The proportional hazards assumption was tested using
the scaled Schoenfeld residuals [38] Chemokine concentrations
Table 1. Baseline characteristics and biomarker levels of the study population according to the occurrence of a cardiovascular
event within six months of follow-up, Bad Nauheim ACS II registry.
Event during follow-up
No (n=539) Yes (n=70) P-value
Baseline characteristics
Age
1– years 64613 66612 0.29
Gender (% male) 70 73 0.62
Body mass index
1–k g / m
2 27.964.4 27.866.3 0.83
Hypertension (% yes) 66 60 0.29
Hyperlipidemia (% yes) 41 33 0.21
Diabetes (% yes) 18 34 ,0.01
Smoking (% yes) 32 26 0.28
Family history of CVD (% yes) 21 9 0.02
History of AMI (%yes) 10 16 0.15
Prior revascularization procedure (% yes) 15 19 0.83
Blood drawing
3,5– hrs 5.9 (2.5–13.9) 5.0 (2.3–10.3) 0.93
Baseline biomarkers levels
2
CCL3/MIP-1a – pg/ml 25.8 (14.9–36.5) 31.4 (17.2–42.2) 0.09
CCL5/RANTES – ng/ml 25.4 (12.3–39.7) 30.7 (14.2–48.2) 0.13
CCL18/PARC – ng/ml 54.0 (36.3–80.5) 66.9 (43.3–104.8) ,0.01
TnT – ng/ml 0.21 (0.04–0.78) 0.29 (0.06–0.90) 0.12
hsCRP – mg/l 3.07 (1.37–7.70) 7.40 (1.89–19.8) ,0.01
NT-proBNP – pg/ml 523 (156–1805) 1326 (305–5549) ,0.01
CK-MB – ng/ml 12.8 (4.5–40.9) 11.3 (4.5–48.1) 0.61
CK-MB max
4– ng/ml 174 (0.00–834) 269 (0.00–1307) 0.36
Creatinine – mg/dl 0.89 (0.77–1.08) 1.15 (0.84–1.42) ,0.01
Patient status upon admission
UAP (%) 10.6 13.9 0.32
STEMI (%) 55.4 58.3 0.71
NSTEMI (%) 33.5 29.2 0.51
Killip Class $2 (% yes) 7 7 0.93
Right coronary artery stenosis (% yes) 6 17 ,0.01
Left coronary artery stenosis (% yes) 45 41 0.58
ST-segment elevation (% yes) 9 4 0.16
T-segment inversion (% yes) 5 9 0.22
Left ventricular ejection fraction
1,6 (%) 48611 44613 0.04
CVD: cardiovascular disease; AMI: acute myocardial infarction; TnT: Troponin T; CRP: C-Reactive Protein; NT-proBNP: N-terminal pro-Brain Natriuretic Peptide; CK-MB:
Creatinine Kinase-MB; UAP: unstable angina pectoris; STEMI: ST-segment elevated myocardial infarction; NSTEMI: Non-ST-segment elevated myocardial infarction.
1Presented as mean 6 sd,
2Presented as median (interquartile range),
3Time of blood drawing since onset of symptoms,
4based on values of 513 event free patients and 68 event patients,
5based on values of 516 event free patients and 63 event patients,
6based on values of 480 event free patients and 53 event patients.
doi:10.1371/journal.pone.0045804.t001
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considered as the reference category. Confounding effects of age
at baseline (years), sex, body mass index (bmi) (kg/m
2),
hypertension (yes/no), hyperlipidemia (yes/no), diabetes (yes/
no), smoking (yes/no), a positive family history of cardiovascular
disease (yes/no), ST-segment depression present on baseline
ECG (yes/no), previous AMI (yes/no), previous revascularization
(yes/no), and baseline levels NT-proBNP (pg/ml), CKMB (ng/
ml), hsCRP (mg/l) and TnT (ng/ml) were evaluated for their
effect on the relationship between chemokine concentrations and
risk of future events. Those variables that altered the estimate for
the exposure coefficient between statistical models with and
without the potential confounder by more than 10% were
included in the analyses. Both univariate and multivariable Cox
models were performed for fatal and non-fatal events combined,
as well as for both endpoints separately.
In order to evaluate the added prognostic value of the
chemokines on top of that provided by conventional predictors
of future cardiovascular events, receiver-operating characteristic
(ROC) curves were constructed for each endpoint, using the
predicted values from multivariable regression models with and
without the studied chemokines. Since standard models to derive
ROC curves do not exist for survival data, we used logistic
regression models with a dichotomous clinical endpoint as
dependent variable (yes/no event during follow-up). The area
under the ROC curve (AUC), or c-statistic, were compared
according to the method described by Hanley et al. [39]. This
method accounts for the fact that the c-statistic from the predicted
values from the models with and without the chemokines were
derived from the same sample of patients.
Two-sided P-values ,0.05 were considered to indicate statistical
significance. All analyses were performed with the STATA
statistical software package (version 10.0).
Results
Of the total study population, 609 patients (80%) had complete
information on baseline biomarker concentrations, traditional risk
predictors for cardiovascular disease and other covariates. Average
follow-up time was 189 days (189614.1 days) during which a total
of 70 patients suffered an event. Figure 1 shows Kaplan Meier
curves for the fatal (n=48) and the non-fatal events (n=22) during
follow-up. The majority of the fatal events had occurred in patients
shortly after admission. Comparison of both event functions with
the log-rank test showed that fatal events occurred significantly
earlier during follow-up than non-fatal events (p,0.05).
Baseline characteristics of the study population are presented in
table 1 according to the occurrence of an adverse event during
follow-up. Compared with the 539 patients who remained event-
free during follow-up, the event population was enriched in
patients with diabetes and left coronary artery stenosis, while a
family history of cardiovascular disease was seen less frequently.
Median serum concentrations of CCL18/PARC, hsCRP, NT-
proBNP and creatinine were significantly higher in patients with
an event than in patients without an event (p,0.01).
Being important measures of the degree of myocardial damage,
left ventricular ejection fraction and end diastolic diameter and -
mass were comparable between UAP, NSTEMI and STEMI
patients (data not shown).
In Table 2, results are presented for the relationship between
the chemokines under study and the risk of adverse events during
follow-up (fatal and non-fatal events combined). We divided
Table 2. Hazard Ratios (95% confidence intervals) for a future cardiovascular event1 during 200 day follow-up in patients with the
acute coronary syndrome, according to baseline levels of CCL3/MIP-1a, CCL5/RANTES and CCL18/PARC, Bad Nauheim ACS II
registry.
Tertiles of biomakers
2 Event during follow-up
No (n=539) Yes (n=70)
Univariate HR
(95% CI) Multivariate HR
3 (95% CI)
CCL3/MIP-1a
Tertile 1 (low) 187 21 1.00 (Reference) 1.00 (Reference)
Tertile 2 189 18 0.83 (0.44–1.55) 0.92 (0.49–1.75)
Tertile 3 (high) 163 31 1.67 (0.97–2.94) 1.60 (0.90–2.83)
p-value for trend 0.267 0.279
CCL5/RANTES
Tertile 1 (low) 177 20 1.00 (Reference) 1.00 (Reference)
Tertile 2 182 17 0.86 (0.45–1.64) 1.10 (0.56–2.18)
Tertile 3 (high) 180 33 1.63 (0.93–2.84) 1.99 (1.10–3.61)
p-value for trend 0.009 0.001
CCL18/PARC
Tertile 1 (low) 185 17 1.00 (Reference) 1.00 (Reference)
Tertile 2 179 21 1.29 (0.68–2.44) 1.49 (0.78–2.85)
Tertile 3 (high) 175 32 1.88 (1.05–3.39) 1.81 (0.98–3.32)
p-value for trend ,0.001 0.001
HR: hazard ratio; CI: confidence interval.
1A cardiovascular event is defined as the occurrence of death, an acute myocardial infarction or an urgent revascularization procedure.
2Tertile boundaries for CCL3/MIP-1a: 18.7–33.3 pg/ml, CCL5/RANTES: 16.2–134.15 ng/ml, CCL18/PARC: 43.0–70.9 ng/ml.
3Adjusted for age, sex, diabetes, smoking, family history of cardiovascular disease and baseline levels of NT-proBNP, CK-MB and TnT.
doi:10.1371/journal.pone.0045804.t002
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PLOS ONE | www.plosone.org 5 September 2012 | Volume 7 | Issue 9 | e45804biomarker concentrations into tertiles to avoid creating too small
subgroups given the relatively low number of follow-up events.
Univariate and multivariate HRs were highly similar. Compared
to patients in the lowest tertile of CCL5/RANTES and CCL18/
PARC, patients in the highest tertile were associated with an
increased risk of adverse events. A similar observation was seen for
patients in the highest tertile of CCL3/MIP-1a, albeit statistical
significance was not reached.
When performing analyses for fatal and non-fatal end points
separately (table 3), we observed positive associations between the
chemokine levels and risk of future fatal events. Patients in the
highest tertile of CCL3/MIP-1a, CCL5/RANTES and CCL18/
PARC had a 2 to 3.4-fold higher risk of mortality during follow-
up, compared to patients in the lowest tertiles. A statistically
significantly linear trend was observed over the tertiles of CCL5/
RANTES and CCL18/PARC (p,0.001). No relationship was
apparent for the three chemokines and the risk of non-fatal events.
The number of cases in these subgroups was very small and
warrants caution when interpreting the risk estimates.
Next, we examined the risk of adverse events according to the
number of chemokines with concentrations in the highest tertile
(table 4). Since the number of events in the patient group with all
biomarkers in the lowest tertile was too small to be taken as
reference group, we considered the group with at least 1
biomarker in the highest tertile as reference. For fatal and non-
fatal events combined, we observed that patients with all three
chemokines in the highest tertile were related to a statistically
significantly increased risk of adverse events, when compared to
patients with at least one chemokine in the highest tertile (HR:
2.71, 95%CI: 1.14–4.91). Patients with all chemokine levels in the
lowest tertile had a decreased risk (HR: 0.49, 95%CI: 0.25–0.96).
This pattern was similar for the fatal events; compared to the
reference group, patients with all three chemokines in the lowest
tertile were associated with a decreased risk of fatal events (HR:
0.29, 95%CI: 0.10–0.85), whereas patients with all three
chemokine levels in the highest tertile were related to an increased
risk (HR: 2.52, 95%CI: 1.11–5.65). Moreover, for both endpoints
we observed a statistically significant trend for an increasing risk of
an event with an increasing number of chemokine concentrations
in the highest tertile (p#0.018). Unfortunately, small subgroups
prohibited meaningful analyses for the non-fatal events.
Based on the observed positive relationships between the
chemokines and the risk of fatal events - as opposed to non-fatal
events - during patient follow-up, we next investigated the markers
added prognostic value to predict the occurrence of fatal events on
top of that provided by known risk predictors (figure 2). After
constructing the ROC curves, the c-statistics appeared to increase
only marginally when - separately - CCL3/MIP-1a, CCL5/
RANTES or CCL18/PARC were added to the regression model
that included known predictors of fatal events (figure 2A–C).
Inclusion in the model of all three chemokines simultaneously
however, increased the c-statistic statistically significantly from
0.74 to 0.81 (p=0.007) (figure 2D).
Discussion
High levels of CCL3/MIP1a, CCL5/RANTES and CCL18/
PARC were found to be independently associated with short-term
fatal events in patients with ACS. Furthermore, risk increased with
an increasing number of chemokines in the highest concentration
tertile. Considering known predictors of fatal events, CCL3/
MIP1a, CCL5/RANTES and CCL18/PARC provided addition-
al prognostic information only when added to the model
simultaneously. In our ACS patients, no relationships were
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PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e45804observed between chemokine levels and the risk of non-fatal events
during follow-up.
Our finding that CCL3/MIP1a, CCL5/RANTES and
CCL18/PARC are independent risk predictors of future fatal
events confirms and extends results from two earlier studies in
which we showed that CCL5/RANTES and CCL18/PARC were
associated with refractory UAP [32] and CCL3/MIP1a with
future ischemia events [36]. In addition, the present results
indicated that the risk of follow-up events increased with an
increasing number of chemokine levels in the highest tertile and
that risk estimation improved when considering all three
biomarkers simultaneously. The value of a multi-marker strategy
has already been advocated by Zethelius and co-workers [40].
They reported an evident increase in the risk of cardiovascular
mortality with an increasing number of elevated biomarker
concentrations. Furthermore, several studies have reported inter-
actions between prognostic biomarkers [41,42,43]. For example,
levels of interleukin-10 were only predictive for death and non-
fatal AMI in patients with elevated CRP levels [44]. Both these
results and the current findings plead for a multi-marker strategy
over a single-marker approach.
In agreement with the results of Zethelius and co-authors [40],
the current findings further imply that a combination of multiple
biomarkers together with established risk predictors can improve
risk prediction in diseased individuals. Namely, all three biomark-
ers together with known predictors of fatal events in ACS patients
increased the c-statistic significantly, when compared with the
known risk predictors alone. Still, the question of whether this
increased prognostic value is also of clinical relevance requires
further investigation in studies with larger patient samples and
higher numbers of events during follow-up.
Our observation that CCL3/MIP1a, CCL5/RANTES and
CCL18/PARC levels were associated with the risk of fatal events,
but not non-fatal events, is in line with the results of a recent study
in elderly subjects with either pre-existing vascular disease or an
increased risk of vascular disease due to smoking, hypertension or
diabetes [45]. The authors observed that the inflammatory
markers interleukin-6 and CRP were more strongly associated
with the risk of fatal vascular events than with the risk of non-fatal
events. In search of a possible explanation, we noticed a large
difference between the timing of fatal and non-fatal events during
follow-up. As the Kaplan-Meier curves showed (figure 1), the
majority of the fatal events occurred already shortly after the start
of follow-up. The median time-to-event of fatal events in our study
was merely 5 days, whereas non-fatal events occurred much later
during follow-up with a median time-to-event of 120 days. The
fact that a large number of fatalities occurred early during follow-
up may thus imply that high concentrations of CCL3/MIP1a,
CCL5/RANTES and CCL18/PARC indicate a high risk of short-
term occurring events. We observed that patients with fatal events
had higher levels of CCL3/MIP1a, CCL5/RANTES and
CCL18/PARC than patients with non-fatal events and appeared
to have suffered a larger infarct reflected by a) a larger proportion
of patients with STEMI at the time of admission (68.1% in
patients with fatal events versus 36% in patients with a non-fatal
event, p=0.01), b) a higher incidence of Killip class $2 (0% in
patients with non-fatal events and 10.6% in patients with fatal
events, p=0.09) and c) a smaller average ejection fraction of the
heart (39.5% in patients with fatal events versus 48.4% in patients
with non-fatal events, p=0.01).
In the current study sample, diabetes was relatively often
present in subjects that experienced an event during follow-up.
Diabetes is known to be associated with increased risk of
cardiovascular disease [46] and all-cause mortality [47], although
the underlying mechanisms remain to be clarified. Consequently,
the presence of diabetes may confound the relationship between
the biomarkers under study and the risk of a future fatal or non-
fatal event. Since the exclusion of all cases with diabetes would
drastically decrease statistical power, we have adjusted all Cox
regression models for the presence of diabetes.
Figure 2. Receiver operating characteristics curves and c-statistics for logistic regression models predicting fatal events during
follow-up in a subgroup of patients with acute coronary syndromes for CCL3/MIP-1a (A), CCL5/RANTES (B), CCL18/PARC (C) and all
markers combined (D). Established risk predictors include age, sex, diabetes, smoking, family history of cardiovascular disease, baseline levels of
NT-proBNP, CK-MB, and TnT.
doi:10.1371/journal.pone.0045804.g002
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PLOS ONE | www.plosone.org 7 September 2012 | Volume 7 | Issue 9 | e45804A few limitations of this study should be noted. First, co-
morbidities such as cancer, acute or chronic infections, and
autoimmune/inflammatory diseases, were not registered for the
patients included in the cohort. Possibly, certain co-morbidities
may influence circulating chemokine levels. The fact that hsCRP
levels were not extremely high suggests that the possible presence
of infectious or inflammatory co-morbidities was low. Second,
blood samples were stored for approximately 3.5 years (average
storage time: 3.060.5 years) before measuring chemokine
concentrations. It is known that long term storage and repeated
freeze/thaw cycles of samples may cause blood marker degrada-
tion [48,49], which then leads to biased results of the association
between blood markers and endpoint. As such, we carefully
evaluated the chemokine concentrations, storage time and time to
event/censoring. Biomarker levels appeared not to have changed
over time and were not correlated with event time (see figure S1).
Furthermore, blood samples have not undergone repeated freeze/
thaw cycles, but were used immediately upon defrosting. The
average storage time was similar both patients with and without
and an event during follow-up. Third, the relatively small number
of events in our cohort, in particular the number of non-fatal
events, warrants caution when interpreting the results of subgroup
analyses. Rather than to focus on the actual size of the risk
estimates, we prefer to look at the direction in which the
associations are pointing. Despite low power, our results confirm
those of previously published research. Future studies will need
larger cohorts to validate our findings and to perform more
detailed subgroup analyses to unravel the potential clinical
importance of chemokines in (short-term) risk prediction in ACS
patients. In addition, detailed subgroup analyses may provide clues
to the underlying molecular mechanism.
In conclusion, chemokines CCL3/MIP1a, CCL5/RANTES
and CCL18/PARC are independently associated with the risk of
short-term fatal events in ACS patients, in which the risk increases
with an increasing number of elevated chemokine concentrations.
The current results plead in favour of a multi-marker strategy as
opposed to a single-marker approach. The biomarkers’ added
value for risk stratification lies in their combination, which
improves risk prediction beyond that of a model based on known
event-predictors in patients with ACS. The clinical relevance of
our results for the current cardiovascular practice deserves further
investigation in studies with larger patient populations.
Supporting Information
Figure S1 Time-to-event for acute coronary syndromes
patients according to the occurrence of an event during
follow-up and correlations between storage time, time-
to-event and chemokine levels. Time-to-event (days) for
event free patients represents time of censoring. As to be expected,
time-to-event differed between patients with and without an event
during follow-up. Storage time and time-to-event correlated
poorly in event-free patients (section B), and a correlation was
absent in patients with an event during follow-up. Importantly,
CCL3/MIP1a, CCL5/RANTES and CCL18/PARC levels had
not decreased with increasing storage time in both patients with
and without an event (sections C, E; and G). Likewise, we did not
observe any correlation between chemokine concentrations and
time-to-event (sections D, F and H).
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